巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Oncternal Therapeutics

    ONCT
    1.045
    0.050
    5.00%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Oncternal Therapeutics - 延遲價格・最後更新於 01/07 12:14
    最高位
    1.130
    最低位
    1.030
    開市價
    --
    前收市價
    1.100
    成交量(千)
    16.01
    成交額(百萬)
    0.13
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    51.65
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    4.790 - 0.690
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Oncternal Therapeutics
    證券代碼
    ONCT.US
    所屬板塊
    Biotechnology
    公司業務
    Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
    發行量
    49429054
    公司總部
    12230 El Camino Real, Suite 300
    公司網址
    https://www.oncternal.com
    公司電郵
    rvincent@oncternal.com
    公司電話
    +1 858 434-1113
    暫無內容

    關於

    Oncternal Therapeutics(ONCT.US)所屬的行業板塊為Biotechnology。
    Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
    詳細公司背景可參考: https://www.oncternal.com